Roslindale, MA, United States of America

Aleksandra Rudnitskaya

This inventor holds 53 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 2 EPO patents, primarily in HDAC Inhibitors (CPC class C07D). Top assignees: Forma Therapeutics, Inc., Valo Health, Inc., Valo Early Discovery, Inc.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aleksandra Rudnitskaya. Retrieved from https://idiyas.com/inventor/aleksandra-rudnitskaya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 9.1

ph-index = 14

Forward Citations = 570(Granted Patents)

Forward Citations (Not Self Cited) = 124(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

34 out of 125

Forma Therapeutics, Inc.

Valo Early Discovery, Inc.

patents

4. 1 out of 312

H. Lee Moffitt Cancer Center and Research Institute, Inc.

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

Areas of Expertise:

HDAC11 Inhibitors

Hydroxamic Acids

Bicyclic Compounds

Alpha-Cinnamide

Isoindolines

3-Aryl Compounds

4-Amido Compounds

3-Alkyl Compounds

Fused Bicyclic

Methods Using Inhibitors

Compositions

Inhibitors

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12479807 - METHODS USING HDAC11 INHIBITORS (2025-11-25),

2. 12304904 - Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors (2025-05-20),

3. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2025-04-01),

4. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors (2024-03-05),

5. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2024-02-06),

6. 11702412 - Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors (2023-07-18),

7. 11535607 - Isoindolines as HDAC inhibitors (2022-12-27),

8. 11414392 - [6,6] fused bicyclic HDAC8 inhibitors (2022-08-16),

9. 11345672 - Methods using HDAC11 inhibitors (2022-05-31),

10. 11279681 - 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2022-03-22),

11. 11274085 - 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2022-03-15),

12. 11274084 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2022-03-15),

13. 10988450 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2021-04-27),

14. 10988441 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors (2021-04-27),

15. 10870645 - Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors (2020-12-22),

Title: Innovations by Aleksandra Rudnitskaya

Introduction

Aleksandra Rudnitskaya is a prolific inventor based in Roslindale, MA, USA. With an impressive portfolio of 50 patents, she has made significant contributions to the field of biochemistry, particularly in the development of innovative therapies for cancer and other diseases.

Latest Patents

Rudnitskaya's latest patents include groundbreaking work on alpha-cinnamide compounds and compositions that act as HDAC8 inhibitors. This invention focuses on inhibitors of histone deacetylases, particularly HDAC8, which are instrumental in treating cancer and a variety of other disorders. Another notable patent is for 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids, which serve as inhibitors of zinc-dependent histone deacetylases. This innovation is relevant for the treatment of diseases associated with HDAC, like HDAC6.

Career Highlights

Throughout her career, Aleksandra has worked with esteemed companies such as Forma Therapeutics, Inc. and Valo Health, Inc. These roles provided her with a robust platform to further her research and development in the medical and pharmaceutical sectors.

Collaborations

Rudnitskaya has collaborated with numerous talented professionals, including her coworkers Pui Yee Ng and Xiaozhang Zheng. These partnerships have likely fostered innovative ideas and effective solutions in their shared field of expertise.

Conclusion

Aleksandra Rudnitskaya serves as an exemplary figure in the realm of patent innovation. Her extensive portfolio and contributions to HDAC inhibition reflect her commitment to advancing medical science, ensuring her place among the notable inventors in her field.

Profile summary based on public USPTO records.